Answers are grounded in this paper and cite their sources.
BACKGROUND Although eukaryotic translation initiation factor 5B (EIF5B ) is implicated in the pathogenesis of multiple malignancies, its functional impact in colonic adenocarcinoma (COAD) is still not well defined. AIM To determine EIF5B ’s role, mechanisms, and therapeutic associations in COAD. METHODS To assess the prognostic value of EIF5B , we integrated pan-cancer bioinformatic screening with clinical validation in COAD cohorts. The oncogenic function and molecular regulations were evaluated through in vitro and in vivo assays, multi-omic pathway enrichment, Western blotting, rescue experiments, immune infiltration and drug-sensitivity modeling. RESULTS Our results showed significant overexpression of EIF5B in COAD tissues, and its correlation with unfavorable patient outcomes. Functional analysis revealed that EIF5B induced migration, proliferation, and invasion in vitro , as well as promoted tumorigenesis in vivo through phosphorylation of mitogen-activated protein kinase 1 (MAPK1). In addition, the immune microenvironment exhibited a suppressed phenotype, accompanied by decreased predictive scores for programmed cell death protein 1/cytotoxic T lymphocyte-associated antigen-4 blockade and reduced predicted sensitivity to chemotherapeutic agents. EIF5B expression, immune evasion, and drug sensitivity were associated with the MAPK signaling pathway. CONCLUSION EIF5B mediated phosphorylation of MAPK1 regulates the progression of COAD, suggesting EIF5B as potential therapeutic target for overcoming resistance against chemotherapy and immunotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: